Presentation is loading. Please wait.

Presentation is loading. Please wait.

Log2 Fold change (MR57 R/S)

Published byLars Jonasson Modified over 5 years ago

Similar presentations

Presentation on theme: "Log2 Fold change (MR57 R/S)"— Presentation transcript:

1 Log2 Fold change (MR57 R/S)
Supplementary Figure 1 A B C E Sensitive Resistant D MR57 Phalloidin staining Gene Log2 Fold change (MR57 R/S) VIM 6,74 FGFR1 4,38 ZEB1 4,24 TGFB1I1 4,09 CDH2 (N-Cadherin) 3,93 TGFB2 3,92 SNAI1 3,75 TGFA -4,19 EPCAM -5,75 CDH1 (E-Cadherin) -5,78 ICAM1 -6,53 G HES E-Cadh N-Cadh Vimentin MR210 Pre-crizotinib Post-lorlatinib F MR57 HES ALK E-Cadh N-Cadh Vimentin pSRC pMAPK Ki-67 CD31 Podoplanin Glut1 CA-IX b catenin CD47 CD68 Pre- crizotinib Post- lorlatinib H I J K MR57 Sensitive MR57 Resistant Lorlatinib (nM) Saracatinib (nM) E-Cadherin N-Cadherin Vimentin Actin

Download ppt "Log2 Fold change (MR57 R/S)"

Similar presentations

AB C Breast cancer Gas6 RNA Seq D E F Figure S1. AXL and GAS6 expression correlates with a mesenchymal signature. (A) Scatter plot representing the RNA.

AB C Breast cancer Gas6 RNA Seq D E F Figure S1. AXL and GAS6 expression correlates with a mesenchymal signature. (A) Scatter plot representing the RNA.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.

Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.
10 0 1 2 3 4 0 1 2 3 4 59% Ter119 CD71 10 0 1 2 3 4 0 1 2 3 4 13% 10 0 1 2 3 4 0 1 2 3 4 1.5% +/+ki/ki 10 0 1 2 3 4 0 20 40 60 80 100 2.71 10 0 1 2 3 4.

% Ter119 CD % % +/+ki/ki
Supplementary Figure S1 a

Supplementary Figure S1 a
Relative to 18S rRNA Supplementary Figure S1. H2228 and H3122 cells express HK1 and HK2 mRNAs. The qPCR was performed as described in Figure 5 and the.

Relative to 18S rRNA Supplementary Figure S1. H2228 and H3122 cells express HK1 and HK2 mRNAs. The qPCR was performed as described in Figure 5 and the.
  TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

  TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson
89 PSA recurrences over median follow-up of 11.3 years

89 PSA recurrences over median follow-up of 11.3 years
Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.

Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.
A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.

A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.
Supplementary Figure 1 (log fold change relative to untreated control)

Supplementary Figure 1 (log fold change relative to untreated control)
Figure S1, FGFR2 copy gain and overexpression in H716 cells A

Figure S1, FGFR2 copy gain and overexpression in H716 cells A
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
a b SUM149PT Motility Invasion C V C V

a b SUM149PT Motility Invasion C V C V
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
New Standards of Care in ALK-Translocated Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC
تحليل الحساسية Sensitive Analysis.

تحليل الحساسية Sensitive Analysis.
A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.
Volume 12, Issue 6, Pages (December 2007)

Volume 12, Issue 6, Pages (December 2007)
Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response  Jeroen Dekervel,

Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response  Jeroen Dekervel,

Similar presentations

Ads by Google